Evidence map›Paper›PMID 29400661›Full record

ArticleCancer biomarkers : section A of Disease markers2018

The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma.

Richard Weiten, Tim Müller, Doris Schmidt, Susanne Steiner, Glen Kristiansen, Stefan C Müller, Jörg Ellinger, Isabella Syring

Open access · hybridAbstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. International journal of surgical pathology · 2023
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Richard WeitenClinic for Urology and Paediatric Urology, University Hospital of Bonn, 53127 Bonn, Germany.
Tim MüllerInstitute of Pathology, University Hospital of Bonn, 53127 Bonn, Germany.
Doris SchmidtClinic for Urology and Paediatric Urology, University Hospital of Bonn, 53127 Bonn, Germany.
Susanne SteinerInstitute of Pathology, University Hospital of Bonn, 53127 Bonn, Germany.
Glen KristiansenInstitute of Pathology, University Hospital of Bonn, 53127 Bonn, Germany.
Stefan C MüllerClinic for Urology and Paediatric Urology, University Hospital of Bonn, 53127 Bonn, Germany.
Jörg EllingerClinic for Urology and Paediatric Urology, University Hospital of Bonn, 53127 Bonn, Germany.
Isabella SyringClinic for Urology and Paediatric Urology, University Hospital of Bonn, 53127 Bonn, Germany.
University Hospital Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectiveMED15 is a part of the multiprotein Mediator complex which is involved in the transcription of polymerase (Pol) II-dependent genes. Several studies in this field have reported altered expressions of distinct subunits in human malignancy. However, the role of MED15 in renal cell carcinoma (RCC) has not be investigated yet.

methodsFirst, we performed an RNA expression and survival analysis of MED15 in RCC by using the database cBioPortal. To confirm these data on the protein level, we executed immunohistochemical (IHC) staining against MED15 on a tissue microarray containing 184 samples of the most common subtypes of the tumour at the various stages. Further, we performed functional analysis including proliferation, migration, and invasion assays on the RCC cell lines A-498 and ACHN following the siRNA-mediated MED15 knockdown.

resultsOn the mRNA level, higher expression of MED15 was associated with worse patient survival rates. IHC staining validated this tendency, unfortunately the results were not significant. However, supporting this tendency, in vitro-assays showed a significant decrease in proliferation, migration, and invasion after knockdown of MED15.

conclusionThe research concludes that MED15 does seem to play a tumour promoting role in the progression and metastatic spread of renal cell carcinoma.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellDisease ProgressionFemaleHumansKaplan-Meier EstimateKidney NeoplasmsMaleMediator ComplexMiddle AgedNeoplasm InvasivenessBiomarkers, TumorMED15 protein, humanMediator ComplexMED15Mediator complexrenal cell carcinomatumour promoter

Identifiers

PMID29400661
PMCPMC13078339
OpenAlexW2786928260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.